Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Myriad Genetics, Inc’s stock clocked out at $15.00, down -1.45% from its previous closing price of $15.22. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 0.9 million shares were traded. MYGN stock price reached its highest trading level at $15.6781 during the session, while it also had its lowest trading level at $14.77.
Ratios:
To gain a deeper understanding of MYGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 19, 2024, initiated with a Equal-Weight rating and assigned the stock a target price of $32.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $35.
On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $29.Scotiabank initiated its Sector Outperform rating on June 27, 2024, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1365528064 and an Enterprise Value of 1428756224. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.66 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 1.735 whereas that against EBITDA is -42.146.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $14.91. The 50-Day Moving Average of the stock is -34.63%, while the 200-Day Moving Average is calculated to be -36.24%.
Shares Statistics:
It appears that MYGN traded 767.05K shares on average per day over the past three months and 1127750 shares per day over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 87.61M. Insiders hold about 3.76% of the company’s shares, while institutions hold 100.16% stake in the company. Shares short for MYGN as of 1730332800 were 4482742 with a Short Ratio of 5.84, compared to 1727654400 on 4190757. Therefore, it implies a Short% of Shares Outstanding of 4482742 and a Short% of Float of 6.909999999999999.
Earnings Estimates
The firm’s stock currently is rated by 13.0 analysts. The consensus estimate for the next quarter is $0.0, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.17 and $0.12 for the fiscal current year, implying an average EPS of $0.13. EPS for the following year is $0.14, with 13.0 analysts recommending between $0.29 and -$0.18.
Revenue Estimates
In the current quarter, 12 analysts expect revenue to total $213.56M. It ranges from a high estimate of $218M to a low estimate of $210.7M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $196.6MFor the next quarter, 12 analysts are estimating revenue of $213.31M. There is a high estimate of $219.46M for the next quarter, whereas the lowest estimate is $207.4M.
A total of 14 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $845M, while the lowest revenue estimate was $837.7M, resulting in an average revenue estimate of $840.84M. In the same quarter a year ago, actual revenue was $753.2MBased on 14 analysts’ estimates, the company’s revenue will be $888.27M in the next fiscal year. The high estimate is $921.4M and the low estimate is $875M.
